5 Dumbest Things on...
Health Care: Drugs
Elan Corp PLC (ELN: NYSE)
$12.47 0.11 | 0.89%
05/24/13 - 04:04 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 431.30M | 271.70M | 422.50M | 836.50M |
| Receivables | 193.50M | 167.70M | 191.60M | 192.40M |
| Inventories | 0.00 | 23.80M | 39.00M | 53.50M |
| Other Current Assets | 222.80M | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 1.41B | 518.00M | 920.50M | 1.16B |
| Property, Plant & Equipment, Gross | 138.00M | 146.10M | 695.80M | 657.50M |
| Accumulated Depreciation & Depletion | 125.30M | 62.90M | 408.30M | 364.70M |
| Property, Plant & Equipment, Net | 12.70M | 83.20M | 287.50M | 292.80M |
| Intangibles | 3.00M | 102.50M | 119.40M | 159.70M |
| Other Non-Current Assets | 54.40M | 723.80M | 278.70M | 301.50M |
| Total Non-Current Assets | 230.70M | 1.24B | 1.10B | 1.19B |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 1.64B | 1.75B | 2.02B | 2.35B |
| Accounts Payable | 102.00M | 46.40M | 39.20M | 52.40M |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 19.00M | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 359.70M | 276.30M | 481.70M | 250.50M |
| Long Term Debt | 600.00M | 615.00M | 1.27B | 1.54B |
| Deferred Income Taxes | 600.00K | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 61.70M | 60.70M | 71.10M | 61.00M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 662.30M | 675.70M | 1.34B | 1.60B |
| Total Liabilities | 1.02B | 952.00M | 1.82B | 1.85B |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 618.20M | 801.80M | 194.30M | 494.20M |
| Common Par | 36.50M | 36.20M | 35.90M | 35.80M |
| Additional Paid In Capital | 352.40M | 6.49B | 6.44B | 6.41B |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | 273.90M | -5.68B | -6.24B | -5.92B |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | -44.60M | -37.40M | -43.10M | -36.10M |
| Total Capitalization | 1.22B | 1.42B | 1.46B | 2.03B |
| Total Equity | 618.20M | 801.80M | 194.30M | 494.20M |
| Total Liabilities & Stock Equity | 1.64B | 1.75B | 2.02B | 2.35B |
| Total Common Shares Outstanding | 594.95M | 589.35M | 585.20M | 583.90M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 592.40M | 587.60M | 584.90M | 506.80M |
| Diluted Weighted Shares Outstanding | 592.40M | 593.50M | 584.90M | 506.80M |
| Number of Employees | 245 | 412 | 1219 | 1321 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with ELN
- Portfolio NameUser Type
- ContributorMost-Active Stocks for the ...
- ContributorMost-Active Stocks for the ...
- ProTPG-Axon Capital
- Contributor22 Biopharma Stocks With Br...
- UserGFNN Stockdiagnostics 13
- ContributorBreakout Stocks Of The Week...
- UserGFNN Stockdiagnostics
- ContributorRelative Strength Trades fo...
- ContributorStocks At New 52-Week Highs...
- ProRobert Bruce
Latest ELN Headlines from TheStreet
- Dollar Strength Hits Oil, Gold
05.13.13 | 08:05 am - Stock Futures Lower Ahead of Retail Sales 05.13.13 | 06:05 am
- Why This Fund Manager Is Short Ziopharm 03.22.13 | 07:03 am
- SAC to Pay Record Insider Trading Penalty 03.16.13 | 11:03 am
- Dow Sets Another Record as Stocks Rise 03.11.13 | 04:03 pm
- You Have to Love a Lucrative 'Drug Deal' 02.28.13 | 06:02 am
- Royalty Pharma: Don't Let Elan Piss Away $3 Billion On Stupid Acquisitions 02.25.13 | 09:02 am
- 2 Hot Stocks to Trade (or Not) 02.07.13 | 02:02 pm
- Before the Bell: Feb. 6 02.06.13 | 08:02 am
- The Digital Skeptic: Insider Trading? Why Even Bother? 12.04.12 | 08:12 am
Press Releases for ELN
- Royalty Pharma Discloses Acceptance Levels Of Original Offer For Elan Pursuant To Irish And United States Regulatory Requirements - PR Newswire 05.24.13 | 07:05 am
- Royalty Pharma Reduces Acceptance Condition To 50% Plus One Share - PR Newswire 05.23.13 | 06:05 am
- Royalty Pharma Increases Offer For Elan To $12.50 Per Share In All Cash - PR Newswire 05.20.13 | 11:05 am
- Royalty Pharma Submits Formal Cash Offer For Elan Corporation, Plc ("Elan") - PR Newswire 05.02.13 | 07:05 am
- Royalty Pharma Announces Firm Offer To Acquire Elan - PR Newswire 04.15.13 | 07:04 am
- New TYSABRI Data Reaffirm Substantial Efficacy In Treatment Of People With MS And Demonstrate Stability Of Anti-JCV Antibody Status - Business Wire 03.18.13 | 07:03 am
- Elan Discloses Filing Of Share Repurchase Tender Offer Documentation - Business Wire 03.12.13 | 01:03 pm
- Elan Provides Update On Tysabri Transaction And $1bn Share Repurchase - Business Wire 03.08.13 | 04:03 pm
- Elan’s Response To Royalty Pharma Statement Of Today - Business Wire 03.06.13 | 09:03 am
- Elan Announces Further Unlocking Of Value To Benefit Shareholders - Business Wire 03.04.13 | 01:03 am
Partner Headlines for ELN
- Acorda: A Biotech Company To Consider - Seeking Alpha 04.13.13 | 09:04 am
- Benzinga's Top Pre-Market Gainers - Benzinga 04.12.13 | 09:04 am
- After Hours Most Active for Feb 6, 2013 : T, BMY, FCX, KMI, NOK, HCBK, QQQ, ELN, GMCR, VMED, NWSA, WCRX - NASDAQ 02.06.13 | 09:02 pm
- Stocks Lower In Choppy Trade; Aruba, Trimble Slide - Investor's Business Daily 02.06.13 | 03:02 pm
- Pre-Market Most Active for Feb 6, 2013 : ELN, QQQ, BAC, BBRY, ZNGA, NOK, GSK, VMED, KB, SNY, ARMH, CLDX - NASDAQ 02.06.13 | 01:02 pm
- Biogen Stock Hits New High On Tysabri Buyout - Investor's Business Daily 02.06.13 | 10:02 am
- Alkermes Trades Tightly, Holds In Buying Range - Investor's Business Daily 01.17.13 | 02:01 pm
- Alkermes' Acquisition Proves To Be Game-Changer - Investor's Business Daily 11.30.12 | 05:11 pm
- Dissecting George Soros' Recent Moves, Part 4: Stake Reductions And Liquidations - Seeking Alpha 11.24.12 | 08:11 am
- Feds Circling SAC Capital; Mathew Martoma Goes Down in $276 Million Insider Trading Sting - Benzinga 11.21.12 | 05:11 pm
